Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74.4M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
25.5M
-
Shares change
-
-1.78M
-
Total reported value, excl. options
-
$25.3M
-
Value change
-
-$3.29M
-
Put/Call ratio
-
0.97
-
Number of buys
-
12
-
Number of sells
-
-20
-
Price
-
$0.99
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q2 2022
56 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock as of Q2 2022.
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.5M shares
of 74.4M outstanding shares and own 34.35% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6.94M shares), TANG CAPITAL MANAGEMENT LLC (3.3M shares), ADAMS STREET PARTNERS LLC (3.28M shares), MILLENNIUM MANAGEMENT LLC (2.69M shares), CHI Advisors LLC (2.21M shares), BVF INC/IL (1.37M shares), VANGUARD GROUP INC (1.27M shares), RENAISSANCE TECHNOLOGIES LLC (963K shares), BlackRock Inc. (506K shares), and Artal Group S.A. (500K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.